The Practice of Pharmaceutical Patent Litigation: Part II

April 30, 2019 9:15am

Laura Fairneny
Partner
Quinn Emanuel Urquhart & Sullivan, LLP (New York, NY)

Gary E. Hood
Shareholder, IP Division Chair
Polsinelli PC (Chicago, IL)

Benjamin C. Hsing
Partner
McGuire Woods (New York, NY)

Bruce J. Koch
Associate General Counsel, Head of Patent Litigation
Purdue Pharma L.P. (Stamford, CT)

Christie Matthaei
Partner
Knobbe Martens (Seattle, WA)

Steven H. Sklar
Shareholder
Leydig, Voit & Mayer Ltd. (Chicago, IL)

Laura A. Vogel
Senior Dir., Assoc. General Counsel of IP
Tesaro, Inc.

Jeanna M. Wacker
Partner
Kirkland & Ellis LLP (New York, NY)

Track Moderator

Guy Donatiello
Senior Vice President, Intellectual Property
Endo Pharmaceuticals

9:15

Joint Defense Groups: A Risk Benefit Analysis for the Hatch-Waxman Practitioner

  • Evaluating the benefits and detriments of joint defense groups in ANDA cases
  • Maximizing efficiency and minimizing risk by protecting join legal interests resourcefully
  • Devising brand name strategies for addressing litigation with joint defense groups
  • Establishing clear leadership at the out-set to simplify future occurrences
  • Understanding when and how many consulting firms to employ in order to avoid the “too many cooks” phenomenon
 

10:00

Claim Construction and the Recent Application of the Printed Matter Doctrine: Exploring Consequences for Obviousness Determinations

  • Understanding the proper role of the printed matter doctrine in obviousness determinations
  • Reviewing recent decisions outlining circumstances when it is proper to give printed matter patentable weight
    • Praxair Distribution v. Mallinckrodt Hosp. Prods. IP
  • Identifying when the application of the printed matter doctrine for claim construction is improper
 

10:45

Selecting and Effectively Using Expert Witnesses in Pharmaceutical Patent Litigation

  • Finding, vetting, retaining, and disclosing expert witnesses in PTAB and District Courtproceedings
  • Understanding the limitations and exclusion of testimony as evidenced by cases where judges enter Daubert orders